Consonance Capital Management’s Myriad Genetics MYGN Stock Holding History

Consonance Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3,309,206	Closed	-$110M	–	32
2019 Q1	$110M	Buy	3,309,206 +938,910	+40%	+$28.6M	6.94%	5
2018 Q4	$68.9M	Buy	2,370,296 +723,966	+44%	+$26M	5.07%	9
2018 Q3	$75.7M	Buy	+1,646,330	New	+$73.2M	4.08%	11
2017 Q4	–	Sell	-1,973,177	Closed	-$71.4M	–	25
2017 Q3	$71.4M	Sell	1,973,177 -1,294,310	-40%	-$36.9M	7.9%	6
2017 Q2	$84.4M	Buy	3,267,487 +291,131	+10%	+$6.18M	9.95%	3
2017 Q1	$57.1M	Buy	2,976,356 +647,424	+28%	+$11.5M	5.99%	7
2016 Q4	$38.8M	Buy	2,328,932 +1,478,932	+174%	+$26.8M	4.26%	11
2016 Q3	$17.5M	Buy	+850,000	New	+$21.6M	1.68%	15
2014 Q3	–	Sell	-507,682	Closed	-$19.8M	–	28
2014 Q2	$19.8M	Sell	507,682 -1,236,468	-71%	-$46M	2.94%	15
2014 Q1	$59.6M	Buy	+1,744,150	New	+$54M	8.87%	2

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Consonance Capital Management's MYGN Position: Q2 2019 in Review

Consonance Capital Management sold out of Myriad Genetics (MYGN) in Q2 2019, closing a stake of 3,309,206 shares — an estimated $110M sold.

Consonance Capital Management first reported a position in MYGN in Q1 2014 and held it in 10 quarters. The position peaked at $110M in Q1 2019. 235 funds tracked by Wall St. Rank hold MYGN as of Q2 2019.

Consonance Capital Management reported no remaining Myriad Genetics position as of Q2 2019 after selling out during the quarter.
Consonance Capital Management sold 3,309,206 Myriad Genetics shares in Q2 2019, an estimated $110M.
Consonance Capital Management first reported a position in Myriad Genetics in Q1 2014 and held it in 10 quarters.
Consonance Capital Management's Myriad Genetics position peaked at $110M in Q1 2019.
235 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2019.

Based on Consonance Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.